• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency.

作者信息

Nishikawa M, Hirabayashi H, Takakura Y, Hashida M

机构信息

Department of Drug Delivery Research, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.

出版信息

Pharm Res. 1995 Feb;12(2):209-14. doi: 10.1023/a:1016222808484.

DOI:10.1023/a:1016222808484
PMID:7784335
Abstract

Hepatic targeting of proteins utilizing the sugar-recognition mechanism was investigated in mice after intravenous injection. Five proteins with different molecular weights, i.e., bovine gamma-globulins (IgG), bovine serum albumin (BSA), recombinant human superoxide dismutase (SOD), soybean trypsin inhibitor (STI), and chicken egg white lysozyme (LZM), were modified with 2-imino-2-methoxyethyl 1-thiogalactoside to obtain galactosylated proteins (Gal-IgG, Gal-BSA, Gal-SOD, Gal-STI, and Gal-LZM). The numbers of galactose residues were 38, 20, 11, 6, and 5 for Gal-IgG, Gal-BSA, Gal-SOD, Gal-STI, and Gal-LZM, respectively. All galactosylated proteins were dose-dependently taken up by the liver and the relative amount accumulated in the liver was decreased with an increase of the administered dose. At low doses (0.05 and 0.1 mg/kg), Gal-IgG, Gal-BSA, and Gal-SOD could be taken up by the liver up to more than 70-80% of dose within 10 min after intravenous injection, but the maximum amounts accumulated in the liver were approximately 40 and 30% of the dose for Gal-STI and Gal-LZM, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency.
Pharm Res. 1995 Feb;12(2):209-14. doi: 10.1023/a:1016222808484.
2
Galactosylated proteins are recognized by the liver according to the surface density of galactose moieties.肝脏根据半乳糖部分的表面密度识别半乳糖基化蛋白。
Am J Physiol. 1995 May;268(5 Pt 1):G849-56. doi: 10.1152/ajpgi.1995.268.5.G849.
3
Molecular Design of Bisphosphonate-Modified Proteins for Efficient Bone Targeting In Vivo.用于体内高效骨靶向的双膦酸盐修饰蛋白的分子设计
PLoS One. 2015 Aug 19;10(8):e0135966. doi: 10.1371/journal.pone.0135966. eCollection 2015.
4
Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice.半乳糖基化乳剂及包封的普罗布考在小鼠体内的生物分布特征,用于亲脂性药物的肝细胞选择性靶向递送
Pharm Res. 2004 Jun;21(6):932-9. doi: 10.1023/b:pham.0000029280.39882.ff.
5
Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery.半乳糖基化聚-L-谷氨酸作为肝脏特异性药物递送的可生物降解载体的研发及药代动力学
Pharm Res. 1996 Jun;13(6):880-4. doi: 10.1023/a:1016053128569.
6
Disposition characteristics of glycosylated poly(amino acids) as liver cell-specific drug carrier.糖基化聚氨基酸作为肝细胞特异性药物载体的处置特性
J Drug Target. 1998;6(3):229-39. doi: 10.3109/10611869808997897.
7
Design of polymeric prodrugs of prostaglandin E(1) having galactose residue for hepatocyte targeting.具有半乳糖残基用于肝细胞靶向的前列腺素E(1)聚合物前药的设计。
J Control Release. 1999 Nov 1;62(1-2):253-62. doi: 10.1016/s0168-3659(99)00045-0.
8
Pharmacokinetic analysis of hepatic uptake of galactosylated bovine serum albumin in a perfused rat liver.灌注大鼠肝脏中半乳糖基化牛血清白蛋白肝摄取的药代动力学分析
J Control Release. 1998 Jan 2;50(1-3):309-17. doi: 10.1016/s0168-3659(97)00157-0.
9
Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice.一种肝细胞特异性前列腺素E(1)聚合物前药的研发及其预防小鼠四氯化碳诱导的暴发性肝炎的潜力。
J Pharmacol Exp Ther. 1999 Sep;290(3):1242-9.
10
Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice.通过一氧化氮肝脏靶向作用预防小鼠缺血/再灌注损伤
J Control Release. 2009 Nov 16;140(1):12-7. doi: 10.1016/j.jconrel.2009.07.013. Epub 2009 Jul 29.

引用本文的文献

1
Molecular Design of Bisphosphonate-Modified Proteins for Efficient Bone Targeting In Vivo.用于体内高效骨靶向的双膦酸盐修饰蛋白的分子设计
PLoS One. 2015 Aug 19;10(8):e0135966. doi: 10.1371/journal.pone.0135966. eCollection 2015.
2
In vivo kinetics and biodistribution analysis of neoglycoproteins: effects of chemically introduced glycans on proteins.新糖蛋白的体内动力学和生物分布分析:化学引入聚糖对蛋白质的影响。
Glycoconj J. 2014 May;31(4):273-9. doi: 10.1007/s10719-014-9520-3. Epub 2014 Apr 5.
3
Bioconjugation of oligonucleotides for treating liver fibrosis.

本文引用的文献

1
Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins.铟-111-二乙三胺五乙酸标记的受体靶向蛋白的细胞内代谢
J Nucl Med. 1993 Oct;34(10):1728-38.
2
Disposition characteristics of protein drugs in the perfused rat kidney.蛋白质药物在灌注大鼠肾脏中的处置特征。
Pharm Res. 1993 Jun;10(6):823-7. doi: 10.1023/a:1018996808153.
3
Control of in vivo fate of albumin derivatives utilizing combined chemical modification.利用联合化学修饰控制白蛋白衍生物的体内命运
用于治疗肝纤维化的寡核苷酸生物共轭
Oligonucleotides. 2007 Winter;17(4):349-404. doi: 10.1089/oli.2007.0097.
4
Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro.半乳糖神经酰胺脂质体包裹的5-氟尿嘧啶在体内外的抗肝癌作用
World J Gastroenterol. 2005 May 7;11(17):2643-6. doi: 10.3748/wjg.v11.i17.2643.
5
Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice.半乳糖基化乳剂及包封的普罗布考在小鼠体内的生物分布特征,用于亲脂性药物的肝细胞选择性靶向递送
Pharm Res. 2004 Jun;21(6):932-9. doi: 10.1023/b:pham.0000029280.39882.ff.
6
Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition.半乳糖基化脂质体在体内对肝细胞的靶向效率:脂质组成的影响。
Pharm Res. 2002 Dec;19(12):1808-14. doi: 10.1023/a:1021433206081.
7
Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery.半乳糖基化聚-L-谷氨酸作为肝脏特异性药物递送的可生物降解载体的研发及药代动力学
Pharm Res. 1996 Jun;13(6):880-4. doi: 10.1023/a:1016053128569.
8
Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.用于靶向给药的大分子载体系统:生物分布的药代动力学考量
Pharm Res. 1996 Jun;13(6):820-31. doi: 10.1023/a:1016084508097.
J Drug Target. 1994;2(2):157-65. doi: 10.3109/10611869409015905.
4
Human hepatic lectin. Physiochemical properties and specificity.人肝凝集素。理化性质与特异性。
J Biol Chem. 1980 May 25;255(10):4607-13.
5
The preparation and labeling of DTPA-coupled albumin.二乙三胺五乙酸偶联白蛋白的制备与标记
Int J Appl Radiat Isot. 1982 May;33(5):327-32. doi: 10.1016/0020-708x(82)90144-2.
6
Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features.合成寡糖与肝脏半乳糖/ N - 乙酰半乳糖胺凝集素的结合。对精细结构特征的依赖性。
J Biol Chem. 1983 Jan 10;258(1):199-202.
7
Tc-99m galactosyl-neoglycoalbumin: in vitro characterization of receptor-mediated binding.锝-99m半乳糖基新糖白蛋白:受体介导结合的体外特性研究
J Nucl Med. 1984 Jul;25(7):779-87.
8
Physiologically based pharmacokinetic modeling: principles and applications.基于生理学的药代动力学建模:原理与应用。
J Pharm Sci. 1983 Oct;72(10):1103-27. doi: 10.1002/jps.2600721003.
9
Carbohydrate-specific receptors of the liver.肝脏的碳水化合物特异性受体。
Annu Rev Biochem. 1982;51:531-54. doi: 10.1146/annurev.bi.51.070182.002531.
10
The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins.表面碳水化合物在肝脏对循环糖蛋白的识别和转运中的作用。
Adv Enzymol Relat Areas Mol Biol. 1974;41(0):99-128. doi: 10.1002/9780470122860.ch3.